Blood test aims to catch lung cancer earlier in smokers

NCT ID NCT06145750

Completed Diagnosis Sponsor: Delfi Diagnostics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving doctors access to a blood test called FirstLook increases lung cancer screening rates among people at high risk. The test looks for DNA fragments in the blood that may signal lung cancer. Researchers compared screening rates in practices that could order the blood test versus those that could not.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FirstLook blood test
What this could lead to: If successful, this blood test could help doctors identify more people with early lung cancer, leading to earlier treatment and better outcomes.
What could go wrong: This is a small, completed study with only 28 participants. The test is not a replacement for CT scans, and its real-world impact on screening rates may be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma disease lung cancer lung disorder lung neoplasm respiratory system disorder respiratory tract neoplasm Thoracic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

DARTNet Institute

Aurora, Colorado, 80045, United States
Duke University

Durham, North Carolina, 27705, United States
University Of Florida

Jacksonville, Florida, 32209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.